Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV)

NCT05236673 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05236673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
July 28, 2022
Completion date
April 30, 2025
Enrollment
676 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure